An ongoing phase III trial is currently investigating the impact on survival of MRTX849 in combination with cetuximab versus chemotherapy in patients with advanced CRC harboring KRAS G12C mutations (NCT04793958) (230). This evidence concerns the gene KRAS and colorectal carcinoma.